Today’s guest post comes from Layne Martin, VP/GM, Specialty Distribution and Third-Party Logistics at McKesson Life Sciences.
Companies commercializing cell and gene therapies face many novel challenges, including: supply chain logistics, patient access, adherence, outcomes collection, and data analysis. Layne reviews the crucial issues and explains the services needed for success.
McKesson Life Sciences has developed a portfolio of patient-centric solutions to help cell and gene therapy companies. To learn more, download their new white paper: The Key to Commercializing Revolutionary Gene Therapies and Other Orphan Drugs.
Read on for Layne’s insights.
Read more »
Source: Post feed
